Literature DB >> 15997877

Epstein-Barr virus serology in the diagnosis of nasopharyngeal carcinoma.

Madeline M F Wong1, Munn-Sann Lye, Hwee-Ming Cheng, Choon-Kook Sam.   

Abstract

The antibody levels to viral capsid antigen (VCA) and early antigen (EA) of Epstein-Barr virus (EBV) in 164 nasopharyngeal carcinoma (NPC) patients from Sarawak, East Malaysia were significantly higher than those in 147 sex, age and ethnically matched healthy controls. As diagnostic markers of NPC, IgG/VCA at reciprocal titers > or =160 was the most sensitive (89%, with 98% specificity), while IgA/EA at > or =5 was the most specific (100%) but the least sensitive (75%). The sensitivity and specificity of IgA/VCA at reciprocal titers > or =10 were 84% and 97%. IgA/VCA has an advantage over IgG/VCA despite the slightly lower sensitivity due to its consistently more distinct fluorescence reaction. The sensitivity and specificity can be marginally improved by a combination of two tests.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15997877

Source DB:  PubMed          Journal:  Asian Pac J Allergy Immunol        ISSN: 0125-877X            Impact factor:   2.310


  6 in total

1.  Prognostic utility of anti-EBV antibody testing for defining NPC risk among individuals from high-risk NPC families.

Authors:  Kelly J Yu; Wan-Lun Hsu; Ruth M Pfeiffer; Chun-Ju Chiang; Cheng-Ping Wang; Pei-Jen Lou; Yu-Juen Cheng; Patti Gravitt; Scott R Diehl; Alisa M Goldstein; Chien-Jen Chen; Allan Hildesheim
Journal:  Clin Cancer Res       Date:  2011-03-29       Impact factor: 12.531

2.  Complementary determination of Epstein-Barr virus DNA load and serum markers for nasopharyngeal carcinoma screening and early detection in individuals at risk in Tunisia.

Authors:  Nehla Mokni Baizig; Patrice Morand; Jean Marie Seigneurin; Hamouda Boussen; Asma Fourati; Said Gritli; Zeineb Oueslati; Slim Touati; Amor Gamoudi; Mansour Ben Abdallah; Michèle El May; Ahmed El May
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-07-30       Impact factor: 2.503

3.  Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.

Authors:  Junying Guo; Zhaolei Cui; Yuhong Zheng; Xiaoli Li; Yan Chen
Journal:  Pathol Oncol Res       Date:  2020-03-28       Impact factor: 3.201

Review 4.  Nasopharyngeal carcinoma: molecular biomarker discovery and progress.

Authors:  William Chi-Shing Cho
Journal:  Mol Cancer       Date:  2007-01-02       Impact factor: 27.401

5.  Epstein-Barr Virus Enhances Cancer-Specific Aberrant Splicing of TSG101 Pre-mRNA.

Authors:  Huey-Huey Chua; Toshiki Kameyama; Akila Mayeda; Te-Huei Yeh
Journal:  Int J Mol Sci       Date:  2022-02-24       Impact factor: 6.208

6.  Efficacy of Chemiluminescence Immunoassays on VCA-IgA and EBNA1-IgA Antibodies of Epstein-Barr Virus in Diagnosing Nasopharyngeal Carcinoma.

Authors:  Xia Yu; Fugui Li; Weimin Cheng; Biaohua Wu; Huiyun Fang; Fuzhen Xia; Yijun Gong; Wenjing Yu; Pu Liao; Youde Cao; Fenghua Yang; Hong Zhu; Jiang Li; Yajun Huang; Liying Gan; Lei Zhang; Yonggang Lou; Mingfang Ji
Journal:  J Cancer       Date:  2020-10-18       Impact factor: 4.207

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.